Across TCGA pan-cancer cohorts, PRKAG1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRKAG1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher PRKAG1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRKAG1 expression acts as an unfavorable survival marker.
KIRP, LUAD, and KICH are the cancer types where PRKAG1 Mutation most reproducibly stratifies survival.